European Investment Bank supports Evotec´s Innovate strategy with € 75 m loan

Evotec AG and the European Investment Bank („EIB“) announced today that the EIB has granted Evotec an unsecured loan facility of up to EUR 75 m to support Evotec’s Innovate strategy. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/european-investment-bank-supports-evotecs-innovate-strategy-with-eur-75-m-loan-5498

Weiterlesen

Evotec and ABIVAX enter into strategic collaboration to develop novel antiviral agents

Evotec AG and ABIVAX today announced a strategic collaboration to discover and develop novel treatments for multiple serious viral infectious diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-abivax-enter-into-strategic-collaboration-to-develop-novel-antiviral-agents-5496

Weiterlesen

Evotec and Fraunhofer IME-SP sign strategic collaboration on iPSC technology

Evotec AG today announced a strategic collaboration on induced pluripotent stem cell („iPSC“) technology with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME, ScreeningPort. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-fraunhofer-ime-sp-sign-strategic-collaboration-on-ipsc-technology-5486

Weiterlesen

Ad hoc: Evotec AG to acquire Aptuit

Evotec AG today announced that it has entered into a definitive agreement with Aptuit Holdings LLC („Aptuit“) under which Evotec will acquire all operational business of Aptuit for $ 300 m (approx. EUR 256 m) to combine the businesses and expand Evotec’s role as leading player in integrated outsourced drug discovery and development solutions. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-ag-to-acquire-aptuit-5

Weiterlesen

Evotec expands collaboration with STORM Therapeutics on its RNA epigenetic platform

Evotec AG announced today an integrated drug discovery collaboration with STORM Therapeutics („STORM“) to develop new small molecule epigenetic drugs for oncology and other therapeutic areas. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-collaboration-with-storm-therapeutics-on-its-rna-epigenetic-platform-5480

Weiterlesen